Evidence map›Paper›PMID 22123698›Full record

ArticleAntimicrobial agents and chemotherapy2012

Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

George Sakoulas, Arnold S Bayer, Joseph Pogliano, Brian T Tsuji, Soo-Jin Yang, Nagendra N Mishra, Victor Nizet, Michael R Yeaman, Pamela A Moise

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 2 syntheses or guidelines pooled it, 173 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Phospholipid-Coated FeAntibiotics (Basel, Switzerland) · 2026
    Article
  4. Daptomycin and linezolid salvage therapy for persistent ampicillin-susceptibleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026
    Article
  5. Review
  6. Article
  7. Ability of Linezolid to CombatAntibiotics (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2025
    Review
  10. Review
  11. Vancomycin-ResistantJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025
    Article
  12. Repurposing Diflunisal as an Antivirulence Agent AgainstInfectious microbes & diseases · 2025
    Article
  13. Review
  14. Article
  15. Measuring beta-lactam minimum inhibitory concentrations inJournal of clinical microbiology · 2024
    Review
  16. Review
  17. Article
  18. Review
  19. Inhibition ofBioengineered · 2022
    Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

George SakoulasUniversity of California San Diego School of Medicine, La Jolla, California, USA. gsakoulas@ucsd.edu
Arnold S Bayer
Joseph Pogliano
Brian T Tsuji
Soo-Jin Yang
Nagendra N Mishra
Victor Nizet
Michael R Yeaman
Pamela A Moise
University of California, San Diego · USThe Lundquist Institute · USCubist Pharmaceuticals (United States) · USHarbor–UCLA Medical Center · USUniversity at Buffalo, State University of New York · USUniversity of California, Los Angeles · US

Funding

DNA segregation during Bacillus growth and developmentR01GM073898 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POGLIANO, JOSEPH A · 2006 to 2013
$2.4M
DETERMINANTS IN PLATELET MICROBICIDAL PROTEINSR01AI048031 · NIAID · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI YEAMAN, MICHAEL R · 2000 to 2004
$1.6M
NIAID NIH HHS R01 AI048031NIAID NIH HHS R01 AI-39018NIAID NIH HHS R01 AI-48031NIGMS NIH HHS R01 GM073898
6 · The paper itself

Abstract

We studied an ampicillin- and vancomycin-resistant Enterococcus faecium (VRE) isolate from a patient with endocarditis and bacteremia refractory to treatment with daptomycin (6 mg/kg of body weight) plus linezolid. Blood cultures cleared within 24 h of changing therapy to daptomycin (12 mg/kg) plus ampicillin. We examined the effects of ampicillin on daptomycin-induced growth inhibition and killing, surface charge, and susceptibility to several prototypical host defense cationic antimicrobial peptides. MICs and time-kill curves with daptomycin were assessed in the presence and absence of ampicillin. The impact of ampicillin on surface charge was assessed by flow cytometry and a poly-l-lysine binding assay. The effects of ampicillin preexposures upon VRE killing by five distinct cationic peptides of different structure, charge, origin, and mechanism of action were analyzed using the epidermal cathelicidin LL-37, thrombin-induced platelet microbicidal proteins (tPMPs), and a synthetic congener modeled after tPMP microbicidal domains (RP-1), human neutrophil peptide-1 (hNP-1), and polymyxin B (bacteria derived). Fluoroscein-Bodipy-labeled daptomycin was used to evaluate daptomycin binding to VRE membranes in the presence or absence of ampicillin. In media containing ampicillin (25 to 100 mg/liter), daptomycin MICs decreased from 1.0 to 0.38 mg/liter. Based on time-kill analysis and an in vitro pharmacodynamic model, ampicillin enhanced daptomycin activity against the study VRE from a bacteriostatic to a bactericidal profile. VRE grown in ampicillin (25 to 150 mg/liter) demonstrated an incremental reduction in its relative net positive surface charge. When grown in the presence (versus absence) of ampicillin (25 and 100 mg/liter), the VRE strain (i) was more susceptible to killing by LL-37, tPMPs, hNP-1, and RP-1 but not to polymyxin B and (ii) exhibited greater binding to Bodipy-labeled daptomycin. We conclude that ampicillin induces reductions in net positive bacterial surface charge of VRE, correlating with enhanced bactericidal effects of cationic calcium-daptomycin and a diverse range of other cationic peptides in vitro. While the mechanism(s) of such β-lactam-mediated shifts in surface charge remains to be defined, these finding suggest a potential for β-lactam-mediated enhancement of activity of both daptomycin and innate host defense peptides against antibiotic-resistant bacteria.

Indexed as

Drug Resistance, BacterialAmpicillinAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBacteremiabeta-LactamsDaptomycinDrug SynergismDrug Therapy, CombinationEndocarditis, BacterialEnterococcus faeciumHumansMicrobial Sensitivity TestsModels, BiologicalTreatment OutcomeVancomycinAmpicillinAnti-Bacterial AgentsAntimicrobial Cationic Peptidesbeta-LactamsDaptomycinVancomycin

Identifiers

PMID22123698
PMCPMC3264218
OpenAlexW1970747983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.